Patrys Limited (ASX: PAB) has received support for its PAT-SC1 treatment for gastric cancer with a new scientific article showing that it increases survival rates at 10 years.
The article in the Oncology Reports journal found that in a study conducted between 1997 and 2001, a single 20mg dose of PAT-SC1 administered before gastric resection surgery induced cell killing in human primary gastric tumours.
This led to tumour cell regression in over half of PAT-SC1-treated patients.
In the 10 year follow-up study of patients that participated in the trial, survival is significantly higher for PAT-SC1 treated patients as compared to an historical control group of patients that underwent a gastric resection but were not treated with PAT-SC1.
Furthermore, PAT-SC1 was well tolerated in all treated patients with no significant side-effects being observed.
These findings further indicate that PAT-SC1 has a strong potential to be used as an additive therapeutic agent in the treatment of patients with gastric cancers.
Given in combination with radical standard surgery, PAT-SC1 could induce killing of tumour cells in various stages of growth, resulting in an improved survival of these patients.
The company is progressing an out-licensing deal for PAT-SC1.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.